Overall survival
Figure 1 · Panel OS
Panel OS 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Baohui Han, Solange Peters, Anh Tuan Le, Dingzhi Huang, Gang Wu, Lejie Cao, Cam Phuong Pham, Jun Zhao, Kai Wang, Nong Yang, Hua Zhong, Youyou Hu, Stefanie Morris, Verena Lam, Vilma Graupner, Barbara Gitlitz, Elen Hoglander, Christian Schulz, Siow Ming Lee
Chin Med J (Engl) 139(12) 1838-1845
BACKGROUND: Lung cancer remains a significant medical problem in Asia, and improved treatments are needed for patients diagnosed with non-small cell lung cancer (NSCLC), who are frail with poor performance status or substantial comorbidities. This study aimed to investigate the efficacy and safety of first-line atezolizumab vs . single-agent chemotherapy in the Asian subpopulation in IPSOS trial. METHODS: This exploratory analysis of the Asian subpopulation from the phase 3, global, open-label, randomized controlled IPSOS trial evaluated the efficacy and safety of atezolizumab (1200 mg intravenously every 3 weeks) vs . single-agent chemotherapy (investigator's choice of vinorelbine or gemcitabine) as first-line treatment in patients with locally advanced or metastatic NSCLC, who were ineligible for platinum-based chemotherapy. The primary outcome was overall survival (OS); other outcomes were progression-free survival (PFS), objective response rate (ORR), duration of response (DOR), and safety. RESULTS: Seventy patients from China and Vietnam were included. Median OS was 15.8 months in the atezolizumab group vs . 12.5 months in the chemotherapy group; unstratified hazard ratio, 0.74 (95% confidence interval 0.41, 1.35). Median PFS was 8.1 months vs . 5.4 months, ORR was 27.9% vs . 7.4%, and median DOR was 18.7 months vs . 9.3 months, in the atezolizumab group vs . in the chemotherapy group, respectively. All-grade and grade 3-4 treatment-related adverse events (AEs) were less frequent with atezolizumab compared with chemotherapy. Two patients in the atezolizumab group had grade 5 AEs, namely pneumonia and acute left ventricular failure, with the latter considered treatment-related. CONCLUSIONS: Atezolizumab showed encouraging efficacy results and was well tolerated in an Asian subpopulation of patients with NSCLC who were deemed ineligible for standard platinum-based chemotherapy. The findings of this exploratory subpopulation analysis were consistent with those for the global IPSOS population. REGISTRATION: ClinicalTrials.gov , NCT03191786.
2 个 Figure · 2 个 KM 面板
Figure 1 OS in the IPSOS Asian subpopulation by treatment arm (atezolizumab vs. chemotherapy) at data cutoff (April 30, 2022). Atezo: Atezolizumab; Chemo: Chemotherapy; CI: Confidence interval; HR: Hazard ratio; mo: Months; mOS: Median overall survival; No.: Number; OS: Overall survival.
Figure 1 · Panel OS
Panel OS 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 PFS in the IPSOS Asian subpopulation by treatment arm (atezolizumab vs. chemotherapy) at data cutoff (April 30, 2022). Atezo: Atezolizumab; Chemo: Chemotherapy; CI: Confidence interval; HR: Hazard ratio; mo: Months; mPFS: Median progression-free survival; No.: Number; PFS: Progression-free survival.
Figure 2 · Panel PFS_Kaplan-Meier_Plot
Panel PFS_Kaplan-Meier_Plot 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。